A, Timeline with detailed mean (SE) durations of the various treatment phases. Percentages of patients who have been extubated, decannulated from extracorporeal membrane oxygenation (ECMO), and discharged from the hospital are also stated. All data points include 40 patients unless otherwise indicated. B, Cumulative number of events are plotted by date. ICU indicates intensive care unit.
eMethods. Supplemental Text.
eFigure. ECMO Technique.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure. JAMA Surg. Published online August 11, 2020. doi:10.1001/jamasurg.2020.3950
Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress syndrome (ARDS), necessitating prolonged mechanical ventilation.1 In some cases, even ventilatory support fails. Venovenous extracorporeal membrane oxygenation (ECMO) has been used in severe cases of respiratory failure.2 However, the need for prolonged ventilation, sedation, and immobility may limit its long-term benefits.3 The application of ECMO in patients with COVID-19 whose condition has rendered mechanical ventilatory support insufficient is not fully established. We present our experience in using single-access, dual-stage venovenous ECMO, with an emphasis on early extubation of patients while they received ECMO support.
Data were collected retrospectively from 40 consecutive patients with COVID-19 who were in severe respiratory failure and supported with ECMO. Each diagnosis of COVID-19 was confirmed using polymerase chain reaction–based assays. Patients were treated at 2 tertiary medical centers in Chicago, Illinois, from March 17 to July 17, 2020. The research protocol was approved by the institutional review boards of the Advocate Christ Medical Center and the Rush University Medical Center with a waiver for consent because of the inability of patients to give consent. A single-access, dual-stage right atrium–to-pulmonary artery cannula was implanted (eFigure in the Supplement), following which ventilation was discontinued while the patient continued to receive ECMO. Patient selection criteria were similar to those of the ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial group (eMethods in the Supplement).2 The primary outcome was survival following safe discontinuation of ventilatory and ECMO supports. Excel for Office 365 2020 (Microsoft) was used for data analysis.
Care with ECMO was performed in 40 consecutive patients between the ages of 22 and 64 years (mean [SE] age, 48.4 [1.5] years); 30 (75%) were men, 16 (40%) were African American individuals, and 14 (35%) were Hispanic individuals (Table). The mean (SE) body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 34.2 (1.1). Obesity was the primary preexisting condition (28 patients [70%]). All patients reached maximum ventilator support, with 90% placed in a prone position (29 patients [73%]), paralyzed (31 patients [78%]), or both, pre-ECMO; 24 patients (60%) required vasopressors. Eleven patients could not be placed in a prone position because of increasing hemodynamic instability and/or worsening oxygenation or ventilation with pronation. All patients demonstrated considerably elevated levels of inflammatory markers, such as D-dimer and ferritin, prior to ECMO use. The mean (SE) time from intubation to ECMO was 4.0 (0.5) days (Figure, A).
As of July 17, ventilator support has been successfully discontinued in all patients, resulting in a mean (SE) time of 13.0 (2.6) days from ECMO initiation to extubation, while 32 (80%) were no longer receiving ECMO care (Figure, A). Twenty-nine (73%) have been discharged from the hospital while no longer receiving oxygen. Complications have been minimal, with no ischemic strokes, inotropic support, or tracheostomies. Ten patients required reintubation; however, they have all since been extubated. Mortality was 15% (6 patients). The mean duration of each treatment phase is detailed in the Figure, A. The cumulative numbers of events are shown in the Figure, B. All patients were treated with systemic anticoagulation.
We investigated the role of ECMO in patients with severe COVID-19 respiratory failure. Demographics, extent of respiratory failure, and pre-ECMO medical management optimization were similar to those of the EOLIA group.2
The single-access, dual-stage cannula offered several advantages: direct pulmonary artery flow, thus improving oxygenation and ventilation; early mobility once off the ventilator; minimal cannula-associated complications or revisions, dissimilar to femoral cannulations4; and finally, support of the right side of the heart in case of right ventricular dysfunction. Given the higher prevalence of and associated mortality with acute cor pulmonale in patients with COVID-19,5 protecting the right side of the heart was critically important.
Prolonged ventilation, including the need for sedatives and patient immobility, may lead to complications.3 By mid-July, all patients have ceased needing a ventilator. Our specialized team of intensive care unit staff mobilized patients while they received care with the ECMO, promoting active patient participation in the recovery process.
Patients with COVID-19 are prone to developing generalized thrombosis, including intracardiac thrombi.5 We have also observed thrombosis within the ECMO circuits and oxygenators. For these reasons, all patients received systemic anticoagulation.
The limited studies on patients with COVID-19 requiring ECMO have thus far demonstrated poor survival.6 Overall, this study demonstrates promising outcomes, with most patients alive and no longer receiving ventilator care and ECMO support and 73% discharged and no longer receiving oxygen. Complications have been minimal; there were no ischemic strokes, inotropic support, and tracheostomy requirements because of the early extubation strategy. Mortality was 15%.
While this study has limitations because it is still an early, retrospective report on 40 patients, single-access, dual-stage venovenous ECMO with early extubation appears to be safe and effective in patients with COVID-19 respiratory failure. Ongoing studies are required, however, to further define the long-term outcomes of this approach.
Accepted for Publication: July 23, 2020.
Corresponding Author: Antone J. Tatooles, MD, Cardiothoracic and Vascular Surgical Associates SC, Advocate Christ Medical Center, 4400 W 95th St, Ste 308, Oak Lawn, IL 60453 (firstname.lastname@example.org).
Published Online: August 11, 2020. doi:10.1001/jamasurg.2020.3950
Author Contributions: Drs Mustafa and Tatooles had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Mustafa, Alexander, Joshi, Tabachnick, Cross, Tatooles.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Mustafa, Joshi, Cross, Tatooles.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Mustafa, Joshi.
Administrative, technical, or material support: All authors.
Supervision: Mustafa, Alexander, Tabachnick, Cross, Pappas, Tatooles.
Other—performed substantial part of the procedures: Alexander.
Conflict of Interest Disclosures: Dr Tatooles reported serving as a consultant with Abbott Laboratories outside the submitted work. No other disclosures were reported.
Additional Contributions: We would like to thank Gillian Alex, MD, Rush University Medical Center, for help with institutional board review approvals. She was not compensated for this contribution. We would also like to thank all our brave medical staff, including the intensivists, nurses, physician assistants, nurse practitioners, respiratory therapists, perfusionists, physical therapists, and speech and occupational therapists, among others who selflessly took care of the patients.
Additional Information: All authors performed extracorporeal membrane oxygenation–associated care as attending cardiac surgeons.
Create a personal account or sign in to: